Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy
| Autor: | Winson Y. Cheung, Patricia A. Tang, Atul Batra |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Time Factors FOLFIRINOX Leucovorin Antineoplastic Agents Irinotecan Olaparib chemistry.chemical_compound Interquartile range Pancreatic cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Neoplasm Staging Retrospective Studies business.industry Remission Induction Hazard ratio Cancer Middle Aged Prognosis medicine.disease Confidence interval Oxaliplatin Pancreatic Neoplasms Treatment Outcome medicine.anatomical_structure chemistry Female Fluorouracil Pancreas business |
| Zdroj: | American Journal of Clinical Oncology. 44:519-525 |
| ISSN: | 0277-3732 |
| Popis: | OBJECTIVES The POLO (Pancreas Cancer Olaparib Ongoing) trial demonstrated improvement in progression-free survival (PFS) with olaparib maintenance in advanced pancreatic cancer (APC) patients with germline BRCA1/2 mutations who had disease control after 16 weeks of platinum-based first-line therapy. However, in the real-world, the first assessment is usually performed at 12 weeks. Therefore, this study aimed to identify the proportion of real-world patients with APC that have disease control at 12 weeks (DC12) after FOLFIRINOX, assess any associations of baseline variables with DC12, and to determine the effect of DC12 on PFS and overall survival (OS). METHODS APC patients treated with first-line FOLFIRINOX from 2011 to 2018 in Alberta, Canada, were identified. We conducted an analysis of baseline characteristics to identify factors associated with DC12 and to compare the PFS and OS of patients with DC12 to those with earlier disease progression. RESULTS We identified 165 APC patients treated with FOLFIRINOX with unknown BRCA1/2 status, of which 56% were men, and the median age at diagnosis was 59 years (interquartile range, 38 to 75 y). Of these, 72 (44%) had DC12. Lower serum carbohydrate antigen 19.9 and normal serum albumin were associated with a higher likelihood of DC12. The PFS and OS of patients with DC12 was significantly higher than those with earlier progression (9.3 vs. 2.5 mo; hazard ratio, 0.22; 95% confidence interval, 0.15-0.32; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|